Global Aurora-A Kinase Inhibitors Pipeline Insight Report 2021: TransThera Biosciences, Eli Lilly and Co, Takeda Oncology, Wigen Biomedicine, TT-00420, LY-3295668, Alisertib, WJ-05129 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Aurora-A Kinase Inhibitors – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This “Aurora-A kinase inhibitors – Pipeline Insight, 2021,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Aurora-A kinase inhibitors pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Aurora-A kinase inhibitors R&D. The therapies under development are focused on novel approaches for Aurora-A kinase inhibitors.

Aurora-A kinase inhibitors Emerging Drugs Chapters

This segment of the Aurora-A kinase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Aurora-A kinase inhibitors Emerging Drugs

LY-3295668: Eli Lilly and Company

LY3295668 (AK-01) is a selective, reversible, ATP-competitive small molecule inhibitor of aurora kinase A (AurA). LY3295668 treatment in xenograft and patient-derived xenograft models resulted in tumor growth arrest or regression of several tumor types with an acceptable safety profile. The potential drug is in phase I/II clinical studies in patients with locally advanced or metastatic solid tumors.

TT-00420: TransThera Biosciences

TT-00420 is an investigational, oral, multi-target, dual mechanism kinase inhibitor targeting both mitosis and tumor micro-environment, for the treatment of triple negative breast cancer (TNBC) and other advanced solid tumors. TT-00420 in November 2019, received an orphan drug designation from the FDA for the treatment of cholangiocarcinoma.

Aurora-A kinase inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Aurora-A kinase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Aurora-A kinase inhibitors

There are approx. 8+ key companies which are developing the Aurora-A kinase inhibitors. The companies which have their Aurora-A kinase inhibitors drug candidates in the most advanced stage, i.e. Phase I/II include, Eli Lilly and Company.

Phases

This report covers around 8+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Aurora-A kinase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Aurora-A kinase inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Aurora-A kinase inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Aurora-A kinase inhibitors drugs.

Aurora-A kinase inhibitors Report Insights

• Aurora-A kinase inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Aurora-A kinase inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

Current Scenario and Emerging Therapies:

• How many companies are developing Aurora-A kinase inhibitors drugs?
• How many Aurora-A kinase inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Aurora-A kinase inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Aurora-A kinase inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Aurora-A kinase inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• TransThera Biosciences
• Eli Lilly and Company
• Takeda Oncology
• Wigen Biomedicine

Key Products

• TT-00420
• LY-3295668
• Alisertib
• WJ-05129

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/pnqjig

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900